Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ch14.18 PK and Safety in High-Risk Neuroblastoma
NCT01592045Phase 2Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Aug 2012
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dinutuximab in neuroblastoma, sponsored by United Therapeutics Corporation. Started Aug 2012; status: completed.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT01592045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01592045.